Science
Alessa Drug Delivery System Overview
- Local drug delivery – potentially eliminates chemical castration-like side effects common to many effective prostate cancer therapies
- <30-minute outpatient procedure using equipment for routine biopsy
- Continuous drug release for 2+ years
- High loading capacity of up to 80% drug in candidate formulations
- All individual components have long track records of human safety
Alessa Founder,
Dr. Pamela Munster Demonstrates Implementation Procedure
Alessa’s Proprietary Prostate Implant Technology
Alessa’s implants are smaller in volume than a typical grain of rice and engineered for local delivery of proven therapies. Each implant combines FDA-approved drugs with a biocompatible polymer matrix that provides sustained release directly at the disease site for months to years.
Once placed, the active compound diffuses concentrically through surrounding tissues, achieving high local drug concentrations while minimizing systemic exposure. This targeted approach enables durable therapeutic effects and maintains an excellent safety profile.
A Platform for Sustained Localized Drug Delivery
By building on the use of clinically validated materials and drugs, while avoiding the body-wide exposure that drives potential systemic toxicities, Alessa’s platform can transform how localized diseases are treated, offering patients a potentially safer, more effective, and less invasive alternative to traditional systemic treatments.
